Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 3/20 | 0.63 |
| ▸ | TTR | P02766 | 4/20 | 0.62 |
| ▸ | AKR1B10 | O60218 | 7/20 | 0.61 |
| ▸ | AKR1B1 | P15121 | 7/20 | 0.61 |
| ▸ | MET | P08581 | 4/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | GMNN | O75496 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.54 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2605865 | 0.93 | TTR (0.71) | ALOX5TTRAKR1B10AKR1B1MET | |
| SCHEMBL2605863 | 0.86 | CA12 (0.64) | TTRAKR1B10AKR1B1METAKR1C3 | |
| SCHEMBL15384083 | 0.84 | TTR (0.86) | ALOX5TTRAKR1B10AKR1B1MET | |
| SCHEMBL15384915 | 0.83 | ALOX5 (0.63) | ALOX5TTRAKR1B10AKR1B1MET | |
| SCHEMBL15384911 | 0.82 | ALOX5 (0.66) | ALOX5TTRAKR1B10AKR1B1MET | |
| SCHEMBL2602740 | 0.81 | AKR1B10 (0.63) | ALOX5TTRAKR1B10AKR1B1MET | |
| SCHEMBL16601907 | 0.81 | AKR1B10 (0.65) | ALOX5TTRAKR1B10AKR1B1MET | |
| SCHEMBL15384912 | 0.81 | AKR1C3 (0.64) | ALOX5TTRAKR1B10AKR1B1MET | |
| SCHEMBL15384897 | 0.80 | AKR1C3 (0.66) | ALOX5TTRAKR1B10AKR1B1MET | |
| SCHEMBL20914956 | 0.80 | TTR (0.87) | ALOX5TTRAKR1B10AKR1B1MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012068038-A2 | CAFFEIC ACID DERIVATIVES AND THEIR USE IN IMPROVING NEURONAL CELL VIABILITY | Chemigen (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20120100122-A1 | COMBINATION THERAPY | Chemigen (US) | 2012-04-26 | — | — | US | disclosed |
| WO-2012054446-A2 | COMBINATION THERAPY | Chemigen (US) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120100122-A1 | COMBINATION THERAPY | SLC25A20, TFAM, NDUFAB1 | ALOX5 1085/4885TTR 341/4885AKR1B10 1036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.